Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer
Publication date
2019-10
Authors
Wisselink, Daan D
Braakhuis, Linde L F
Gallo, Gaetano
van Grevenstein, Wilhelmina M U
van Dieren, Susan
Kok, Niels F M
de Reuver, Philip R
Tanis, Pieter J
de Hingh, Ignace H J T
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
BACKGROUND: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin in addition to cytoreductive surgery (CRS) has recently been questioned in peritoneal metastases of colorectal cancer. Whether this applies to all published CRS/HIPEC regimens is unclear. METHODS: A systematic literature search identified 46 studies on CRS/HIPEC using either oxaliplatin of mitomycin C with at least one oncological outcome parameter RESULTS: Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints. Severe postoperative complication rate seemed significantly higher after oxaliplatin-based CRS/HIPEC. CONCLUSION: Published cohorts on oxaliplatin-based CRS/HIPEC differed essentially from MMC-based procedures, especially considering the application of oxaliplatin-containing neo-adjuvant systemic therapy and shorter exposure time to intraperitoneal chemotherapy in oxaliplatin studies. No meaningful comparison could be made regarding DFS and OS.
Keywords
Antineoplastic Agents/therapeutic use, Colorectal Neoplasms/drug therapy, Combined Modality Therapy, Cytoreduction Surgical Procedures, Humans, Hyperthermia, Induced, Mitomycin/therapeutic use, Oxaliplatin/therapeutic use, Peritoneal Neoplasms/drug therapy, Cytoreductive surgery, Colorectal cancer, Survival, Morbidity, Oxaliplatin, HIPEC, Mitomycin C, Peritoneal metastases, Taverne, Hematology, Oncology, Meta-Analysis, Journal Article, Comparative Study
Citation
Wisselink, D D, Braakhuis, L L F, Gallo, G, van Grevenstein, W M U, van Dieren, S, Kok, N F M, de Reuver, P R, Tanis, P J & de Hingh, I H J T 2019, 'Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer', Critical Reviews in Oncology/Hematology, vol. 142, pp. 119-129. https://doi.org/10.1016/j.critrevonc.2019.06.014